JCJianjun Cheng

Jianjun Cheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianjun Cheng has a total of 247 co-authors. Here are the top co-authors by number of shared publications:

  • Sheng Wang

    Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

    11 shared publications
  • Wenzhong Yan

    Human Institute, ShanghaiTech University, Shanghai 201210, China

    11 shared publications
  • Huan Wang

    Human Institute, ShanghaiTech University, Shanghai, China

    9 shared publications
  • Alan P. Kozikowski

    Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States

    6 shared publications
  • Liang Tan

    Human Institute, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai 201210, China

    6 shared publications
  • Luyu Fan

    Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China

    6 shared publications

Latest Publications

  • Sustained antidepressant-like effects of psychedelics through 5-HT2AR–β-arrestin signaling

    by Licong He, Lingjie Tang, Dongmei Cao, Wenwen Duan, Jing Yu, Pei Zhang, Huiqiong Li, Yumeng Wang, Bing Meng, Huan Wang, et al.

    Psychedelics produce long-lasting antidepressant effects, but their hallucinogenic properties limit clinical use. Using structure-guided design of 5-HT2AR–β-arrestin-biased agonists, we identified β-arrestin signaling as a critical driver of prolonged antidepressant-like effects in mice. Here we show that the slow-dissociation kinetics of lysergic acid diethylamide (LSD) enable progressive accumulation of 5-HT2AR engagement during repeated low-dose administration, approaching the receptor occupancy achieved by an acute high dose while avoiding its high peak concentration. This kinetic separation sustains β-arrestin signaling while limiting robust Gαq-mediated Ca2+ responses. Consistent with this framework, repeated low-dose LSD and repeated low-dose psilocybin pretreatment followed by a high-dose psychedelic challenge produced sustained antidepressant-like behavioral effects in mice. In parallel, these regimens produced no detectable psychedelic-associated behavioral disruption in mice and cynomolgus macaques. Together, these findings uncover the signaling basis of sustained psychedelic efficacy and provide a rational framework for developing nonhallucinogenic psychedelic therapies for psychiatric disorders.

  • Open Access

    Mechanistic Basis for 5-HT2AR Over 5-HT2BR Activation

    by Lingjie Tang, Xin Ji, Yumeng Wang, Dongmei Cao, Huiqiong Li, Licong He, Jianjun Cheng, Sheng Wang

    Selective 5-HT2AR agonism without 5-HT2BR activation is critical for safe psychedelic-inspired therapeutics. Here, we systematically probe the ligand-binding pockets of 5-HT2AR and 5-HT2BR and identify steric and conformational constraints at the side-extended pocket (SEP) and extended binding pocket (EBP) that dictate ligand orientation and receptor signaling. Guided by these insights, we design derivatives across tryptamine and phenethylamine scaffolds that integrate SEP and EBP engagement with scaffold modification to reinforce 5-HT2AR activation while limiting 5-HT2BR activity. Cryo-EM structures of 5-HT2AR and 5-HT2BR bound to IHCH-2330, a selective 5-HT2AR agonist and 5-HT2BR antagonist, confirm the design principle. These findings show differential activation mechanisms between 5-HT2AR and 5-HT2BR and provide a rational framework for engineering safer, functionally selective serotonergic compounds, mitigating 5-HT2BR–mediated side effects while preserving therapeutic efficacy.

  • Open Access

    Structure-based design of subtype-selective psychedelic analogs

    by Huiqiong Li, Lingjie Tang, Jinfeng Zhang, Bing Meng, Dongmei Cao, Yujin Chen, Jing Yu, Huan Wang, Zhi-Jie Liu, Sheng Wang, et al.

    Classical psychedelics exert hallucinogenic and therapeutic effects primarily through activation of serotonin 2 A receptor (5-HT2AR), offering promise as transformative treatments for neuropsychiatric disorders. However, their concurrent activation of 5-HT2BR—associated with cardiac valvulopathy—raises serious safety concerns, underscoring the need for subtype-selective psychedelics. To address this, we determine the cryo-EM structure of 5-HT2AR and perform a comparative structural analysis of the orthosteric binding pockets (OBPs) of 5-HT2AR and 5-HT2BR. Guided by key residue differences, we develop a trigonal pharmacophore model to inform the design of 5-HT2AR-selective agonists that avoid 5-HT2BR activation. Using this model, we design and synthesize two compound series that selectively activate 5-HT2AR while antagonizing 5-HT2BR. Molecular basis of subtype selectivity is confirmed by five additional cryo-EM structures of receptor-ligand complexes. Selected compounds also exhibit antidepressant-like efficacy in animal models. Our findings provide a strategy for the development of safer, subtype-selective psychedelic analogs with therapeutic potential.

  • Targeting peripheral 5-HT2AR enhances antitumor immunity in colorectal cancer

    by YaTing Wen, LingJie Tang, WenWen Duan, QingFei Ren, YangYue Ni, ShiYang Chen, Jun Chen, Lei Yang, Huan Wang, Yuan Chen, et al.


  • Open Access

    Deep learning reveals FLAD1-mediated mitochondrial metabolic reprogramming in hypoxic tumors

    by Xiangyu Zhao, Tao Wu, Sanan Wu, Yujin Chen, Yu Zhang, Jing Chen, Kaixuan Diao, Zaoke He, Jiawei Yan, Tianzhu Lu, et al.


  • Pharmacokinetics-Driven Optimization of Immunotherapeutic Agents Targeting the Adenosine A 2A Receptor (A 2A R) and Histone Deacetylases (HDACs)

    by Wenzhong Yan, Mingshun Feng, Kexin Yang, Chengcheng Yu, Wenxin Zhang, Junjun Liu, Chengying Xie, Jianjun Cheng

    Recent research has identified that adenosine A2A receptor (A2AR) antagonists are promising agents for cancer immunotherapy. However, their limited efficacy as monotherapies remains an unresolved challenge. A2AR/HDAC dual-targeting compounds have demonstrated more potent antitumor efficacy and warrant further investigation. To further improve the drug-like properties of such compounds in our previous work, a pharmacokinetics-driven structural optimization campaign was undertaken and led to the identification of compound 13t (IHCH-3185), which exhibited a markedly enhanced pharmacokinetic profile in mice. Furthermore, 13t retained potent target engagement (A2AR Ki = 7.6 nM, HDAC1 IC50 = 102.9 nM) and demonstrated broad-spectrum antiproliferative activity in vitro. Oral administration of 13t significantly inhibited CT26 and MC38 tumor growth in mice with tumor growth inhibition rates of 68.5% and 71.1%, respectively. This robust activity was attributed to a dual mechanism combining immune stimulation and direct antiproliferative effects. These results make 13t a promising cancer immunotherapy drug candidate.


  • Open Access

    Targeting class I HDACs suppresses oncogenic vulnerabilities and potentiates KRAS/MAPK pathway inhibitors in KRAS-mutant cancers

    by Kexin Yang, Xiaolong Qin, Yafang Wang, Wenzhong Yan, Mingyue Yao, Chengcheng Yu, Chuwei Yu, Shangxuan Shi, Yu Zhao, Lina Zhou, et al.


  • Structure-Guided Design of Novel 5-HT 2A Partial Agonists as Psychedelic Analogues with Antidepressant Effects

    by Rongyan Li, Haohan Yan, Yujin Chen, Yangyang Liu, Lingjie Tang, Jing Yu, Junjun Liu, Huan Wang, Sheng Wang, Jianjun Cheng

    Depression is primarily treated with selective serotonin reuptake inhibitors (SSRIs), which are limited by delayed onset of effects and low rates of remission. Recent studies showed that serotonergic psychedelics such as psilocybin can reduce depressive symptoms both rapidly and enduringly. Such effects have been associated with the activation of the serotonin 2A (5-HT2A) receptor in the central nervous system, which has prompted medicinal chemistry studies of novel 5-HT2A agonists. In this study, we designed and synthesized novel 5-HT2A partial agonists based on the structures of the antipsychotic drug aripiprazole and our previously reported lead compound IHCH-7086. Two series of new compounds were synthesized, a number of which exhibited potent 5-HT2A partial agonist activity in G protein coupling and β-arrestin2 recruitment assays. Compound 28c exhibited antidepressant effects in the mouse tail-suspension test without inducing head-twitch responses, supplementing the growing reservoir of nonhallucinogenic 5-HT2A agonists.


  • Open Access

    Tumor hypoxia adaptation depends on FLAD1 mediated mitochondrial metabolic reprogramming

    by Xiangyu Zhao, Tao Wu, Sanan Wu, Yujin Chen, Yu Zhang, Jing Chen, Kaixuan Diao, Zaoke He, Jiawei Yan, Tianzhu Lu, et al.

    Hypoxia, a hallmark of solid tumors, promotes the malignant progression and is challenging to target. Metabolic reprogramming and the resulting metabolic vulnerabilities provide a promising strategy to target tumor hypoxia. Here we systematically compared the metabolic network differences between hypoxic and non-hypoxic cells, and developed a deep learning model, “DepFormer”, to predict the dependent metabolic genes in hypoxic tumor cells. The performance of DepFormer was validated using CRISPR screening dataset. Oxidative phosphorylation was identified as the most significantly hypoxia-dependent metabolic pathway, and FLAD1 was predicted to be one of the key hypoxia-dependent metabolic genes. FLAD1 locus is amplified, and FLAD1 expression is upregulated in various tumor types, especially in hypoxic tumors. FLAD1 depletion compromises tumor’s adaptation to hypoxia by disrupting mitochondrial complex II activity, leading to an imbalance between succinate and fumarate, and consequent failure to adapt to hypoxia. Subsequently, we identified a drug-like inhibitor of FLAD1, which selectively inhibits the growth of tumor cells under hypoxia. Our findings reveal FLAD1 as an innovative therapeutic target for hypoxic tumors.

  • Open Access

    IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response

    by Mingyue Yao, Wenzhong Yan, Yafang Wang, Yu Zhao, Xiaowei Xu, Yujun Chen, Chengcheng Yu, Yingnian Li, Hualiang Jiang, Jie Shen, et al.

    Background: Despite initial success with FLT3 inhibitors (FLT3is), outcomes for FLT3-ITD acute myeloid leukemia (AML) patients remain unsatisfactory, underscoring the need for more effective treatment options. Epigenetic modifications, such as histone acetylation, contribute to AML’s onset and persistence, advocating the potential for epigenetic therapies. However, the poor specificity of pan-histone deacetylase inhibitors (HDACis) leads to undesirable adverse effects, prompting the need for isoform-specific HDACis. This study aims to explore the antileukemic activities and mechanisms of IHCH9033, a novel class I HDACi, alone or combined with FLT3i in FLT3-ITD AML. Methods: The viability of AML cell lines and primary AML cells treated with HDACis alone or in combination with FLT3i was detected by MTT or CCK8 assay. Flow cytometry was utilized to examine cell apoptosis, cell cycle progression and ROS production. RNA sequencing analysis, RT-qPCR, western blotting, and co-immunoprecipitation assays were employed to elucidate the molecule mechanisms. The in vivo anti-leukemia efficacy was tested in xenografted mice models derived from FLT3-ITD cell lines and primary AML patients. Results: Here, we identified IHCH9033, a novel selective class I HDACi, which exhibited an increased antitumor effect in FLT3-ITD AML through effectively eliminating leukemia burden and overcoming resistance to FLT3i. Mechanically, IHCH9033 selectively inhibited DNA repair in FLT3-ITD AML cells, leading to the accumulation of DNA damage that eventually resulted in cell cycle arrest and apoptosis. Additionally, IHCH9033 induced HSP90 acetylation, FLT3 ubiquitination, and proteasomal degradation of FLT3, thereby inhibiting FLT3 downstream signaling. Notably, IHCH9033 maintained its potency in both FLT3i-resistant AML cell lines and primary-resistant patient samples, and exerted strong synergy with the FLT3i quizartinib, leading to tumor regression in FLT3-ITD/TKD AML xenografts. In patient-derived xenografts, the treatment with IHCH9033, both alone and in combination, led to nearly complete eradication of the AML burden, without significant adverse effects. Conclusions: Our study shows that IHCH9033, a novel class I HDACi with a desirable pharmacological profile, is a promising drug candidate for FLT3-ITD AML, and suggests a strategy of combining class I HDACis and FLT3is in AML clinical trials to increase efficacy and overcome resistance, thus potentially providing a curative treatment option.